These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 26204569

  • 1. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
    Wu BJ, Shrestha S, Ong KL, Johns D, Dunn LL, Hou L, Barter PJ, Rye KA.
    Int J Cardiol; 2015 Nov 15; 199():204-12. PubMed ID: 26204569
    [Abstract] [Full Text] [Related]

  • 2. Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit.
    Wu BJ, Shrestha S, Ong KL, Johns D, Hou L, Barter PJ, Rye KA.
    Arterioscler Thromb Vasc Biol; 2015 Mar 15; 35(3):628-36. PubMed ID: 25633313
    [Abstract] [Full Text] [Related]

  • 3. Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition.
    Wu BJ, Li Y, Ong KL, Sun Y, Shrestha S, Hou L, Johns D, Barter PJ, Rye KA.
    Arterioscler Thromb Vasc Biol; 2017 Dec 15; 37(12):2333-2341. PubMed ID: 29025709
    [Abstract] [Full Text] [Related]

  • 4. The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits.
    Wu BJ, Li Y, Ong KL, Sun Y, Johns D, Barter PJ, Rye KA.
    Sci Rep; 2019 Nov 07; 9(1):16183. PubMed ID: 31700015
    [Abstract] [Full Text] [Related]

  • 5. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
    Reyes-Soffer G, Millar JS, Ngai C, Jumes P, Coromilas E, Asztalos B, Johnson-Levonas AO, Wagner JA, Donovan DS, Karmally W, Ramakrishnan R, Holleran S, Thomas T, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Liu Y, Lassman ME, Gutstein DE, Rader DJ, Ginsberg HN.
    Arterioscler Thromb Vasc Biol; 2016 May 07; 36(5):994-1002. PubMed ID: 26966279
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein.
    Han S, Levoci L, Fischer P, Wang SP, Gagen K, Chen Y, Xie D, Fisher T, Ehrhardt AG, Peier AM, Johns DG.
    Biochim Biophys Acta; 2013 Apr 07; 1831(4):825-33. PubMed ID: 23269286
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis.
    Trinder M, Wang Y, Madsen CM, Ponomarev T, Bohunek L, Daisely BA, Julia Kong H, Blauw LL, Nordestgaard BG, Tybjærg-Hansen A, Wurfel MM, Russell JA, Walley KR, Rensen PCN, Boyd JH, Brunham LR.
    Circulation; 2021 Mar 02; 143(9):921-934. PubMed ID: 33228395
    [Abstract] [Full Text] [Related]

  • 8. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
    Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P, DEFINE Investigators.
    J Clin Lipidol; 2015 Mar 02; 9(1):65-71. PubMed ID: 25670362
    [Abstract] [Full Text] [Related]

  • 9. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
    Simic B, Mocharla P, Crucet M, Osto E, Kratzer A, Stivala S, Kühnast S, Speer T, Doycheva P, Princen HM, van der Hoorn JW, Jukema JW, Giral H, Tailleux A, Landmesser U, Staels B, Lüscher TF.
    Atherosclerosis; 2017 Feb 02; 257():186-194. PubMed ID: 28152406
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R, Joy TR.
    Cardiovasc Ther; 2011 Oct 02; 29(5):327-39. PubMed ID: 20406242
    [Abstract] [Full Text] [Related]

  • 12. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ.
    Curr Opin Lipidol; 2011 Aug 02; 22(4):288-95. PubMed ID: 21587074
    [Abstract] [Full Text] [Related]

  • 13. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH, Akhlaghi F.
    Clin Pharmacokinet; 2013 Aug 02; 52(8):615-26. PubMed ID: 23658137
    [Abstract] [Full Text] [Related]

  • 14. Deficiency of Cholesteryl Ester Transfer Protein Protects Against Atherosclerosis in Rabbits.
    Zhang J, Niimi M, Yang D, Liang J, Xu J, Kimura T, Mathew AV, Guo Y, Fan Y, Zhu T, Song J, Ackermann R, Koike Y, Schwendeman A, Lai L, Pennathur S, Garcia-Barrio M, Fan J, Chen YE.
    Arterioscler Thromb Vasc Biol; 2017 Jun 02; 37(6):1068-1075. PubMed ID: 28428219
    [Abstract] [Full Text] [Related]

  • 15. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F, Thieblemont Q, Muzotte E, Burr N, Urbain I, Sulpice T, Johns DG.
    Eur J Pharmacol; 2014 Oct 05; 740():135-43. PubMed ID: 25008069
    [Abstract] [Full Text] [Related]

  • 16. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H.
    Vasc Health Risk Manag; 2012 Oct 05; 8():323-31. PubMed ID: 22661899
    [Abstract] [Full Text] [Related]

  • 17. Anacetrapib: a potential new therapy for dyslipidemia.
    Robinson LB, Frishman WH.
    Cardiol Rev; 2014 Oct 05; 22(5):253-61. PubMed ID: 24618931
    [Abstract] [Full Text] [Related]

  • 18. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D.
    Curr Opin Investig Drugs; 2009 Sep 05; 10(9):980-7. PubMed ID: 19705341
    [Abstract] [Full Text] [Related]

  • 19. Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques.
    Roddy TP, McLaren DG, Chen Y, Xie D, Dunn K, Kulick A, Szeto D, Forrest G, Albanese K, Donnelly M, Gai C, Gewain A, Lederman H, Jensen KK, Ai X, Vachal P, Akinsanya KO, Cleary MA, Previs SF, Dansky HM, Johns DG.
    Eur J Pharmacol; 2014 Oct 05; 740():410-6. PubMed ID: 24769414
    [Abstract] [Full Text] [Related]

  • 20. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
    Gotto AM, Kher U, Chatterjee MS, Liu Y, Li XS, Vaidya S, Cannon CP, Brinton EA, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P, DEFINE Investigators.
    J Cardiovasc Pharmacol Ther; 2014 Nov 05; 19(6):543-9. PubMed ID: 24737712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.